Disease · MONDO_0005178

osteoarthritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. osteoarthritis. Diseases, record MONDO_0005178. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005178

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: osteoarthritis; Open Targets
Open Targets ID: MONDO_0005178; Open Targets
Other names: Arthritides, Degenerative, Arthritis, Degenerative, Degenerative Arthritides, Degenerative Arthritis, OA, Osteoarthritides, Osteoarthroses, Osteoarthrosis, Osteoarthrosis Deformans, arthrosis, degenerative joint disease; Open Targets
Disease Ontology: DOID:8398; Disease Ontology
MeSH: D010003; MeSH
NCI Thesaurus: C3293; NCI Thesaurus
Highest stage of its drugs: Approval, for 52 of its 214 drugs, from ClinicalTrials.gov, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs214

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Approval	DailyMed	39	32	21	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Approval	DailyMed and PMDA	76	31	31	Drugs and targets
NAPROXEN	CHEMBL154	Small molecule	Approval	DailyMed and TTD	166	23	19	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	25	21	7	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	PMDA	20	19	19	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Approval	DailyMed	169	17	13	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Approval	DailyMed	38	16	2	Drugs and targets
DICLOFENAC	CHEMBL139	Small molecule	Approval	ClinicalTrials.gov, DailyMed and TTD	26	16	16	Drugs and targets
DICLOFENAC SODIUM	CHEMBL1034	Small molecule	Approval	DailyMed	127	15	15	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	56	15	1	Drugs and targets

1 to 10 of 214

See all 214 drugs

Targets201

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	33	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	22	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
OPRM1	Mu-type opioid receptor	16	Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
NR3C1	Glucocorticoid receptor	15	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
OPRK1	Kappa-type opioid receptor	7	Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
SCN4A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	5	Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4985	Drugs and targets
SCN10A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets

1 to 10 of 201

See all 201 targets

Trials446

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 25 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00346216	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	Phase 4	24,081	2017-05-01	Arthritis, Rheumatoid	CELECOXIB, IBUPROFEN, NAPROXEN	Its record names the disease	ClinicalTrials.gov
NCT00141102	Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis	Phase 4	4,484	2010-06-11	Osteoarthritis, Arthritis, Rheumatoid	CELECOXIB, DICLOFENAC, OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03161093	A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip	Phase 3	3,307	2022-11-14	Osteoarthritis, Knee, Osteoarthritis, Hip	FASINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02528188	Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee	Phase 3	3,021	2020-01-10	Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee	TANEZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00809783	Extension Study Of Tanezumab In Osteoarthritis	Phase 3	2,147	2021-05-10	Osteoarthritis	TANEZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03304379	Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip	Phase 3	1,650	2023-02-24	Osteoarthritis, Knee, Osteoarthritis, Hip	FASINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03172780	A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"	Phase 3	1,220	2021-04-20	Osteoarthritis, Knee	DICLOFENAC SODIUM	Its record names the disease	ClinicalTrials.gov
NCT00486434	Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis	Phase 3	1,176	2012-06-28	Osteoarthritis	CALCITONIN, SMC021	Its record names the disease	ClinicalTrials.gov
NCT02121002	Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee	Phase 3	1,176	2021-06-16	Osteoarthritis	DICLOFENAC SODIUM	Its record names the disease	ClinicalTrials.gov
NCT02596451	To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).	Phase 3	1,164	2017-06-28	Osteoarthritis	DICLOFENAC SODIUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 446

See all 446 trials

Comparisons in its trials73

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)	20 of 2,238	81 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms	132 of 2,238	162 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs	5 of 2,238	11 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)	25 of 2,238	92 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Withdrawn Due to GI Adverse Events (AEs)	114 of 2,238	167 of 2,246	4,484	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: serious adverse events	61 of 2,223	61 of 2,237	4,460	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin	45 of 2,184	123 of 2,167	4,351	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview	82 of 2,047	79 of 2,048	4,095	NCT00141102	Trial comparisons
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Alive at the Post Trial Interview	2,018 of 2,047	2,023 of 2,048	4,095	NCT00141102	Trial comparisons
Active Arm vs Placebo Arm: serious adverse events	100 of 585	88 of 584	1,169	NCT00486434	Trial comparisons

1 to 10 of 73

See all 73 comparisons in its trials

Papers from its trials309

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40529153	RESULT	1	PubMed
39548417	RESULT	1	PubMed
38894836	RESULT	1	PubMed
38858713	RESULT	1	PubMed
38708322	RESULT	1	PubMed
38550325	RESULT	1	PubMed
38489855	RESULT	1	PubMed
38411652	RESULT	1	PubMed
38317328	RESULT	1	PubMed
38200939	RESULT	1	PubMed

1 to 10 of 309

See all 309 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005178

GET https://conductscience.org/api/diseases/v1/MONDO_0005178/drugs?page=2

API reference For AI assistants